Richard W Price

List of Publications by Year
in descending order

99 papers	11,026 citations	44069 48 h-index	40979 93 g-index
100 all docs	100 docs citations	100 times ranked	6881 citing authors

#	Article	IF	Citations
1	The AIDS dementia complex: I. Clinical features. Annals of Neurology, 1986, 19, 517-524.	5.3	1,670
2	The AIDS dementia complex: II. Neuropathology. Annals of Neurology, 1986, 19, 525-535.	5.3	1,224
3	The AIDS Dementia Complex. Journal of Infectious Diseases, 1988, 158, 1079-1083.	4.0	635
4	Quinolinic acid in cerebrospinal fluid and serum in HIV-1 Infection: Relationship to clinical and neurological status. Annals of Neurology, 1991, 29, 202-209.	5.3	569
5	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine, 2016, 3, 135-140.	6.1	360
6	HIVâ€Associated Disease of the Nervous System: Review of Nomenclature and Proposal for Neuropathologyâ€Based Terminology. Brain Pathology, 1991, 1, 143-152.	4.1	323
7	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2020, 95, e1754-e1759.	1.1	304
8	Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. Annals of Neurology, 1993, 33, 343-349.	5.3	262
9	AIDS dementia complex and HIVâ€1 brain infection: Clinicalâ€virological correlations. Annals of Neurology, 1995, 38, 563-570.	5.3	257
10	HIVâ€1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2010, 202, 1819-1825.	4.0	255
11	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. Aids, 2012, 26, 1765-1774.	2.2	212
12	HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. PLoS Pathogens, 2011, 7, e1002286.	4.7	203
13	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Research and Therapy, 2010, 7, 15.	1.7	186
14	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186
15	Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Annals of Neurology, 1990, 28, 556-560.	5.3	169
16	Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 196, 1779-1783.	4.0	164
17	Large Differences in Small RNA Composition Between Human Biofluids. Cell Reports, 2018, 25, 1346-1358.	6.4	163
18	Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection. PLoS Pathogens, 2015, 11, e1004720.	4.7	147

#	Article	IF	Citations
19	Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. Journal of Virology, 2010, 84, 2395-2407.	3.4	142
20	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. Journal of Infectious Diseases, 2013, 207, 1703-1712.	4.0	142
21	Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. BMC Infectious Diseases, 2005, 5, 98.	2.9	138
22	Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. Aids, 1999, 13, 1677-1685.	2.2	131
23	Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients. PLoS ONE, 2014, 9, e88591.	2.5	128
24	Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection. Journal of Infectious Diseases, 2008, 197, S294-S306.	4.0	126
25	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology, 2009, 9, 63.	1.8	126
26	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. Journal of Infectious Diseases, 2011, 204, 753-760.	4.0	125
27	Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. Aids, 2014, 28, 2251-2258.	2.2	125
28	CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms. Neurology, 2021, 96, e294-e300.	1.1	118
29	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Review of Molecular Diagnostics, 2017, 17, 761-770.	3.1	114
30	CSF neurofilament protein (NFL) â€" a marker of active HIV-related neurodegeneration. Journal of Neurology, 2007, 254, 1026-1032.	3.6	110
31	Elevated Cerebrospinal Fluid Neurofilament Light Protein Concentrations Predict the Development of AIDS Dementia Complex. Journal of Infectious Diseases, 2007, 195, 1774-1778.	4.0	103
32	The aids dementia complex: Some current questions. Annals of Neurology, 1988, 23, S27-S33.	5.3	96
33	Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 168-173.	2.1	96
34	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. PLoS ONE, 2014, 9, e116081.	2.5	95
35	Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy. Current HIV/AIDS Reports, 2015, 12, 280-288.	3.1	93
36	Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS ONE, 2016, 11, e0157160.	2.5	93

#	Article	IF	Citations
37	Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV. JCI Insight, 2018, 3, .	5.0	85
38	Treatment Benefit on Cerebrospinal Fluid HIVâ€1 Levels in the Setting of Systemic Virological Suppression and Failure. Journal of Infectious Diseases, 2006, 194, 1686-1696.	4.0	83
39	Measuring the ?viral load? in cerebrospinal fluid in human immunodeficiency virus infection: Window into brain infection?. Annals of Neurology, 1997, 42, 675-678.	5.3	79
40	Increased Adhesion Molecule and Chemokine Receptor Expression on CD8+T Cells Trafficking to Cerebrospinal Fluid in HIVâ€1 Infection. Journal of Infectious Diseases, 2004, 189, 2202-2212.	4.0	73
41	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2018, 67, 1697-1704.	5.8	67
42	AIDS Dementia Complex and HIVâ€1 Infection: A View From the Clinic. Brain Pathology, 1991, 1, 155-162.	4.1	66
43	Cerebrospinal fluid response to structured treatment interruption after virological failure. Aids, 2001, 15, 1251-1259.	2.2	59
44	Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects. PLoS ONE, 2013, 8, e66188.	2.5	59
45	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. Clinical Infectious Diseases, 2019, 69, 1345-1352.	5.8	58
46	Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. Journal of Neuroinflammation, 2013, 10, 62.	7.2	55
47	Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of Virology, 2015, 89, 11294-11311.	3.4	54
48	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 544-552.	2.1	52
49	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1132-1140.	4.0	50
50	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e512.	6.0	50
51	Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment. Antiviral Therapy, 2005, 10, 701-707.	1.0	44
52	Defining cerebrospinal fluid HIV RNA escape. Aids, 2019, 33, S107-S111.	2.2	40
53	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal of NeuroImmune Pharmacology, 2013, 8, 1147-1158.	4.1	37
54	Bloodâ€"brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e300.	6.0	36

#	Article	IF	Citations
55	Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. Journal of Neuroinflammation, 2014, 11, 199.	7.2	33
56	Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1154-1160.	1.6	30
57	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987.	2.5	30
58	Evolving Character of Chronic Central Nervous System HIV Infection. Seminars in Neurology, 2014, 34, 007-013.	1.4	29
59	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. Journal of Infectious Diseases, 2018, 217, 1024-1032.	4.0	29
60	Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antiviral Therapy, 2005, 10, 701-7.	1.0	29
61	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. Antiviral Therapy, 2008, 13, 369-374.	1.0	27
62	Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. Journal of NeuroVirology, 2019, 25, 150-161.	2.1	26
63	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. Aids, 2010, 24, 1001-1005.	2.2	25
64	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Journal of Virus Eradication, 2016, 2, 243-250.	0.5	22
65	Neurochemical biomarkers to study CNS effects of COVIDâ€19: A narrative review and synthesis. Journal of Neurochemistry, 2021, 159, 61-77.	3.9	21
66	Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. Journal of NeuroVirology, 2004, 10, 44-51.	2.1	20
67	Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. Aids, 2013, 27, 1145-1149.	2.2	19
68	The Cellular Basis of Central Nervous System HIV-1 Infection and the AIDS Dementia Complex:. Journal of Neuro-AIDS, 1995, 1, 1-29.	0.2	18
69	3.7 How HIV leads to neurological disease. Medical Journal of Australia, 1996, 164, 233-234.	1.7	16
70	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. Aids, 2018, 32, 985-997.	2.2	15
71	What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?. Aids, 2019, 33, S171-S179.	2.2	15
72	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. Clinical Infectious Diseases, 2022, 75, 493-502.	5.8	15

#	Article	IF	Citations
73	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE, 2019, 14, e0226276.	2.5	14
74	Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antiviral Therapy, 2008, 13, 369-74.	1.0	14
75	Undetectable tumor necrosis factor-alpha in a spinal fluid from HIV-1-infected patients. Annals of Neurology, 1992, 31, 687-688.	5.3	13
76	Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence. Aids, 2019, 33, S135-S144.	2.2	13
77	Central nervous system HIV-1 infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 487-505.	1.8	12
78	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). Virulence, 2017, 8, 599-604.	4.4	12
79	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research and Human Retroviruses, 2016, 32, 791-800.	1.1	11
80	Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance. PLoS ONE, 2020, 15, e0236162.	2.5	11
81	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. Current HIV/AIDS Reports, 2019, 16, 76-81.	3.1	9
82	Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection. BMC Neurology, 2021, 21, 494.	1.8	9
83	Increased Neopterin Levels in Brains of Patients with Human Immunodeficiency Virus Type 1 Infection. Journal of Neurochemistry, 1992, 59, 1541-1546.	3.9	8
84	Brain MRI Features of CSF Human Immunodeficiency Virus Escape. Journal of Neuroimaging, 2018, 28, 601-607.	2.0	8
85	AIDS-related vacuolar myelopathy is not associated with coinfection by human T-lymphotropic virus Type I. Annals of Neurology, 1989, 26, 679-681.	5.3	7
86	Cerebrospinal Fluid and Plasma Lipopolysaccharide Levels in Human Immunodeficiency Virus Type 1 Infection and Associations With Inflammation, Blood-Brain Barrier Permeability, and Neuronal Injury. Journal of Infectious Diseases, 2021, 223, 1612-1620.	4.0	7
87	Predicting Efavirenz Concentrations in the Brain Tissue of <scp>HIV</scp>â€Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. Clinical and Translational Science, 2019, 12, 302-311.	3.1	5
88	Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection. Journal of Virus Eradication, 2015, 1, 264-268.	0.5	4
89	Article Commentary: Targeting Chronic Central Nervous System HIV Infection. Antiviral Therapy, 2012, 17, 1227-1231.	1.0	3
90	Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 2020, 6, 19-26.	0.5	3

#	Article	IF	Citations
91	Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation. Microbiology Spectrum, 2022, 10, e0197521.	3.0	2
92	Blood biomarkers for HIV infection with focus on neurologic complicationsâ€"A review. Acta Neurologica Scandinavica, 2022, 146, 56-60.	2.1	2
93	Neuroimmunology of CNS HIV Infection: A Narrative Review. Frontiers in Neurology, 0, 13, .	2.4	2
94	Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
95	Cerebrospinal Fluid Markers in the Management of Central Nervous System HIV Infection and the AIDS Dementia Complex. , 0, , 173-179.		0
96	Title is missing!. , 2019, 14, e0226276.		0
97	Title is missing!. , 2019, 14, e0226276.		0
98	Title is missing!. , 2019, 14, e0226276.		0
99	Title is missing!. , 2019, 14, e0226276.		0